Related Experiment Video

Updated: May 17, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K

Tislelizumab for the treatment of advanced esophageal squamous cell carcinoma

Kazuhiro Shiraishi1, Shun Yamamoto1, Ken Kato1

  • 1Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

Future Oncology (London, England)
|April 21, 2025
PubMed

Insights

Tislelizumab, an immune checkpoint inhibitor, shows efficacy in advanced esophageal squamous cell carcinoma (ESCC). Tislelizumab plus chemotherapy is a recommended first-line treatment for ESCC patients, regardless of PD-L1 status.

Area of Science:

  • Oncology
  • Immunotherapy
  • Gastrointestinal Oncology

Background:

  • Advanced esophageal squamous cell carcinoma (ESCC) presents a poor prognosis with limited therapeutic options.
  • Immune checkpoint inhibitors (ICIs) have emerged as a promising treatment modality for advanced ESCC.
  • Tislelizumab, an anti-Programmed-Death-1 (PD-1) antibody, has demonstrated clinical activity in this patient population.

Purpose of the Study:

  • To review the development and clinical efficacy of tislelizumab in advanced ESCC.
  • To discuss the role of ICIs, including tislelizumab, in the treatment landscape of advanced ESCC.
  • To provide perspectives on future directions for ICI-based therapies in advanced ESCC.

Main Methods:

  • Review of randomized controlled trials (RCTs) evaluating tislelizumab in advanced ESCC.
  • Analysis of data from RATIONALE-302 and RATIONALE-306 trials.
  • Discussion of clinical outcomes and treatment strategies involving tislelizumab and other ICIs.

Main Results:

  • Tislelizumab monotherapy demonstrated efficacy as a second-line treatment for advanced ESCC (RATIONALE-302).
  • Tislelizumab plus doublet chemotherapy showed superior overall survival compared to chemotherapy alone in untreated advanced ESCC (RATIONALE-306).
  • Tislelizumab plus doublet chemotherapy is considered a first-line standard treatment for advanced ESCC, irrespective of PD-L1 expression.

Conclusions:

  • Tislelizumab-based therapies represent a significant advancement in treating advanced ESCC.
  • Tislelizumab plus doublet chemotherapy is a recommended first-line treatment option for advanced ESCC.
  • Further research is needed to optimize the selection and sequencing of various ICI-containing treatments for advanced ESCC.
Keywords:
Esophageal cancerRATIONALE-302RATIONALE-306esophageal squamous cell carcinomaimmune checkpoint inhibitortislelizumab

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.4K
An Ivor Lewis Esophagectomy Designed to Minimize Anastomotic Complications and Optimize Conduit Function09:40

An Ivor Lewis Esophagectomy Designed to Minimize Anastomotic Complications and Optimize Conduit Function

Published on: April 17, 2020

13.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
86
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
441